Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by somweyungguyon Nov 09, 2016 6:13pm
248 Views
Post# 25442500

Financing/analyst partners Cormark and Mackie....

Financing/analyst partners Cormark and Mackie....I was debating their involvement with an old chum earlir today and wondering why they never told the "market" Spectral had achieved the EAP ( expanded access approval ) This essentially allows the PMX to be used in US and Canadian trial sites on an ongoing basis after the trial is completed

Answers?

I also asked why the Cormark analyst kept EDT under review for 360 days ( Jun 4 / 15 - May 30 / 16) and failed to wait just one extra day so that he may include info from the company AGM which he attended

Answers?

As a matter of fact, from the time of the financing they participated in ( Feb.2/16 ), I can't find any real proof that they believed in the company or worked to share any real positives...again going back to the lack of disclosure on the EAP or compassionate care program.  I am relatively new to having analyst coverage and would like a more seasoned player to explain their odd way of supporting a stock they own / owned ??

Cheers,
Sqr
Bullboard Posts